Get the Stockscreener App
10.05
1.52%
0.15
After Hours:
10.34
0.29
+2.89%
Evolent Health Inc stock is traded at $10.05, with a volume of 2.13M.
It is up +1.52% in the last 24 hours and down -10.75% over the past month.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
See More
Previous Close:
$9.90
Open:
$9.8
24h Volume:
2.13M
Relative Volume:
0.84
Market Cap:
$1.18B
Revenue:
$2.35B
Net Income/Loss:
$-74.42M
P/E Ratio:
-10.69
EPS:
-0.94
Net Cash Flow:
$150.93M
1W Performance:
+7.49%
1M Performance:
-10.75%
6M Performance:
-3.83%
1Y Performance:
-56.90%
1-Day Range:
$9.605
$10.29
1-Week Range:
$9.33
$10.29
52-Week Range:
$7.06
$33.48
Evolent Health Inc Stock (EVH) Company Profile
Name
Evolent Health Inc
Sector
Industry
Phone
571-389-6000
Address
1812 NORTH MOORE ST, SUITE 1705, ARLINGTON
Compare EVH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVH
Evolent Health Inc
|
10.05 | 1.16B | 2.35B | -74.42M | 150.93M | -0.94 |
|
VEEV
Veeva Systems Inc
|
284.20 | 46.88B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
56.59 | 10.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
97.00 | 8.54B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
58.75 | 11.03B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
36.98 | 6.17B | 906.14M | -52.62M | 89.62M | -0.3621 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Needham | Buy |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Nov-08-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-11-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-09-24 | Upgrade | Truist | Hold → Buy |
| Apr-22-24 | Initiated | Citigroup | Buy |
| Mar-01-24 | Initiated | Oppenheimer | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-06-23 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-23 | Initiated | UBS | Buy |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Nov-01-22 | Initiated | Truist | Hold |
| Jul-29-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-30-22 | Initiated | Guggenheim | Buy |
| Nov-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-29-21 | Resumed | JP Morgan | Neutral |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Jul-06-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-05-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-05-18 | Resumed | Leerink Partners | Outperform |
| Jun-04-18 | Initiated | Piper Jaffray | Overweight |
| Apr-24-18 | Resumed | JP Morgan | Neutral |
| Sep-20-17 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-02-17 | Initiated | Robert W. Baird | Outperform |
| Mar-14-17 | Initiated | Oppenheimer | Outperform |
| Jan-13-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Oct-28-16 | Resumed | JP Morgan | Overweight |
| Aug-05-16 | Reiterated | FBR Capital | Outperform |
| Jul-26-16 | Initiated | Jefferies | Buy |
| Jul-13-16 | Reiterated | FBR Capital | Outperform |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Jan-06-16 | Initiated | Canaccord Genuity | Buy |
| Jun-30-15 | Initiated | Goldman | Buy |
| Jun-30-15 | Initiated | JP Morgan | Overweight |
| Jun-30-15 | Initiated | Leerink Partners | Outperform |
| Jun-30-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Evolent Health Inc Stock (EVH) Latest News
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline - Yahoo Finance
NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed's next move - Quantisnow
How volatile is Evolent Health Inc. stock compared to the marketFinancial News Tips To Watch Now - jammulinksnews.com
What are Evolent Health Inc. company’s key revenue driversStock Strategy Review That Work - jammulinksnews.com
What are analysts’ price targets for Evolent Health Inc. in the next 12 monthsMaximize your portfolio’s growth potential - jammulinksnews.com
Should I hold or sell Evolent Health Inc. stock in 2025Capitalize on market shifts before others do - jammulinksnews.com
Key External Factors That Drive Evolent Health Inc. Stock Price MovementsSafe High Return Entry Points - metal.it
When is Evolent Health Inc. stock expected to show significant growthExponentially increasing returns - jammulinksnews.com
The Analyst Verdict: Evolent Health In The Eyes Of 5 Experts - 富途牛牛
What drives Evolent Health Inc. stock priceAccelerated investment success - PrintWeekIndia
What makes Evolent Health Inc. stock attractive to long term investorsMarket-crushing profits - jammulinksnews.com
Will Evolent Health Inc. stock split in the near futureOverwhelming profit margins - jammulinksnews.com
Evolent Health Inc. Stock Analysis and ForecastMassive profits - PrintWeekIndia
How Evolent Health Inc. stock reacts to Fed policy changesJaw-dropping returns - jammulinksnews.com
What analysts say about Evolent Health Inc. stockHigh-margin investment plays - Autocar Professional
Elevance Health, EchoStar, Icahn Enterprises, Evolent Health, and The Trade Desk Shares Are Soaring, What You Need To Know - TradingView
Is Evolent Health Inc. a good long term investmentExceptional market positioning - jammulinksnews.com
Evolent Health, Inc (EVH) Stock Analysis: Exploring A 56% Potential Upside Amid Healthcare's Digital Evolution - DirectorsTalk Interviews
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Raises Target Price to $16 - 富途牛牛
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Truist Securities Raises Price Target for Evolent Health (EVH) | - GuruFocus
Evolent Health: Truist Securities Maintains Buy, Raises PT to $16 from $14. - AInvest
Evolent Health Insiders Added US$1.35m Of Stock To Their Holdings - 富途牛牛
Evolent Health Announces Q2 Earnings Date and Major Growth Conference Appearance - Stock Titan
Evolent Health, Inc. (NYSE:EVH) Stock Catapults 35% Though Its Price And Business Still Lag The Industry - simplywall.st
Evolent Health Inc Stock (EVH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
3.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):